Marksans Pharma growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+1,025.1%−88.0%+17.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+1,036.5%−88.5%+35.1%
+1,027.8%−88.4%+33.7%
+997.9%−87.8%+18.7%
+9.8%+21.4%+8.0%
+1,091.8%−87.9%+22.4%
+1,126.3%−88.1%+18.2%
+2,116.8%−91.0%−3.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MARKSANS₹315.35

Marksans Pharma Ltd.

· Pharma & Health
₹ CrorePeersGRANULESMETROPOLISPARKHOSPSJLHLHCGRUBICONSHILPAMEDSPARCMcap ₹14,290 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+17.6-88.0+1,025.1—
EBITDA Growth—+35.1-88.5+1,036.5—
EBIT Growth—+33.7-88.4+1,027.8—
Net Income Growth—+18.7-87.8+997.9—
EPS Growth—+8.0+21.4+9.8—
Total Assets Growth—+22.4-87.9+1,091.8—
Total Equity Growth—+18.2-88.1+1,126.3—
Cash from Operations Growth—-3.0-91.0+2,116.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.